This article is more than 5 years old. Information may no longer be current.

Alcon posts 15.3% increase in global sales for the first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon posted $1.72 billion in global sales for the first quarter, representing a 15.3% increase — or a 9.6% increase excluding the influence of foreign exchange fluctuations and acquisitions — compared with $1.49 billion in global sales reported during the first quarter of 2009.

First-quarter net earnings totaled $573 million, or $1.89 per diluted share, up 26.8% from $452 million, or $1.51 per diluted share, reported during the same period last year.

International sales totaled $995 million, representing a 19.2% increase — or a 9.7% increase excluding the impact of foreign exchange flux — compared with $835 million reported during last year's first quarter. Benefiting from a more favorable economic environment compared to the first quarter of 2009, sales in the United States rose 10.3% during the first quarter of 2010, driven by sales of advanced technology AcrySof IOLs, as well as sustained market share gains in glaucoma pharmaceuticals and consumer eye care products.

Global pharmaceutical sales totaled $728 million, representing a 16.3% increase — or an 11.7% increase on an organic basis — compared with $626 million reported during last year's first quarter. Specifically, global glaucoma pharmaceutical sales rose 24% organically driven by continued sales growth for Azarga ophthalmic suspension (brinzolamide 10 mg/mL and timolol 5 mg/mL) and Azopt (brinzolamide 2%) outside the U.S. In addition, global sales of Travatan (travoprost), Travatan Z (travoprost 0.004%) and DuoTrav (travoprost 0.004%, timolol 0.5%) ophthalmic solutions rose 21% on an organic basis during the first quarter, according to the release.

Sales of infection/inflammation products totaled $230 million, up 13.9% — or 4% excluding foreign exchange flux — compared with $202 million reported during the first quarter of 2009. However, allergy product sales declined 3.5% for the quarter.

First-quarter global surgical sales rose 8.3% on an organic basis, led by a 10.9% reported increase in IOL sales. Specifically, sales of advanced technology IOLs rose 4%, driven by the AcrySof IQ toric and AcrySof IQ ReSTOR +3.0 D lenses.

First-quarter consumer eye care products increased 7.7% percent on an organic basis to $221 million, led by strong sales for Opti-Free Replenish multipurpose disinfecting solution and the Systane family of lubricant eye drops, the release said.

Follow OSNSuperSite.com on Twitter.